Hikma Pharmaceuticals PLC

LSE HIK.L

Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) for the year ending December 31, 2023: 222,368,714

Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) is 222,368,714 for the year ending December 31, 2023, a -1.17% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) for the year ending December 31, 2022 was 225,000,000, a -3.43% change year over year.
Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) for the year ending December 31, 2021 was 233,000,000, a -2.10% change year over year.
Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) for the year ending December 31, 2020 was 238,000,000, a -2.06% change year over year.
Hikma Pharmaceuticals PLC Shares (Diluted, Weighted) for the year ending December 31, 2019 was 243,000,000, a 0.41% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO	Mr. Riad Ali Mishlawi
IPO Date	Nov. 1, 2005
Location	United Kingdom
Headquarters	1 New Burlington Place
Employees	9,100
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Key trends

Past 5 years